The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AFT-50 EndoMAP: A phase IB/II multicohort study of targeted agents and/or immunotherapy for patients with recurrent or persistent endometrial cancer (EC).
 
Evelyn Cantillo
No Relationships to Disclose
 
Tyler J. Zemla
No Relationships to Disclose
 
John William Moroney
Research Funding - AstraZeneca (Inst); Genentech (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Merck (Inst); Mersana (Inst); Sutro Biopharma (Inst); Tesaro (Inst); Verastem (Inst)
 
Edwin A Alvarez
Consulting or Advisory Role - Eisai; EMD Serono; GlaxoSmithKline; Immunogen; OncoSec
Research Funding - Aravive (Inst); Arsenal Biosciences, Inc (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Corcept Therapeutics (Inst); Genentech (Inst); Immunogen (Inst); Merck (Inst); Sumitomo Pharma Oncology (Inst); Tesaro/GSK (Inst); VBL Therapeutics (Inst)
 
Jigna Shah
Employment - Genentech
Stock and Other Ownership Interests - Genentech
Travel, Accommodations, Expenses - Genentech
Other Relationship - Genentech
 
Yvonne Gail Lin
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
Consulting or Advisory Role - Venn Biosciences Corporation
 
Gillian DiLallo
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
Travel, Accommodations, Expenses - Genentech/Roche
 
Joyce F. Liu
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo; Eisai; Genentech/Roche; GlaxoSmithKline; Regeneron; Zentalis
Research Funding - 2X Oncology (Inst); Aravive (Inst); Arch Oncology (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); CytomX Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); IMPAC Medical Systems (Inst); Regeneron (Inst); Vigeo Therapeutics (Inst); Zentalis (Inst)
 
Haider Mahdi
No Relationships to Disclose
 
Angeles Alvarez Secord
Leadership - GOG Foundation
Research Funding - Abbvie (Inst); Aravive (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Eisai (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Mersana (Inst); OncoQuest Pharmaceuticals (Inst); Seagen (Inst); VBL Therapeutics (Inst); Zentalis (Inst)
(OPTIONAL) Uncompensated Relationships - Aravive; GOG Foundation; OncoQuest Pharmaceuticals; Regeneron; VBL Therapeutics
 
Andrew B. Nixon
Consulting or Advisory Role - Leap Therapeutics; Sanofi
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Genmab (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Patent (Inst); Patent Pending (Inst)
 
Sumithra J. Mandrekar
Consulting or Advisory Role - Flatiron Health; Harbinger Oncology, Inc
Other Relationship - Beigene
 
Ursula A. Matulonis
Honoraria - Alkermes; Symphogen
Consulting or Advisory Role - Agenus; Allarity Therapeutics; Blueprint Medicines; Boehringer Ingelheim; Curelab Oncology; Eisai; GlaxoSmithKline; GlaxoSmithKline; Immunogen; Lilly; Merck; NextCure; ProfoundBio; Tango Therapeutics
Speakers' Bureau - Med Learning Group
Research Funding - Fujifilm; Immunogen; Leap Therapeutics; Merck; Mersana; Novartis; SQZ Biotech; Syndax; Tesaro
Travel, Accommodations, Expenses - AstraZeneca; Immunogen
 
David E. Kozono
Honoraria - Reflexion Medical
Consulting or Advisory Role - Genentech
 
Brian M. Slomovitz
Consulting or Advisory Role - AstraZeneca; BioNTech SE; Eisai; EQRx; Genentech; Genmab; Gilead Sciences; GlaxoSmithKline; GOG Foundation; Lilly; Merck; Nuvation Bio; Onconova Therapeutics; Onconova Therapeutics; Regeneron; Seagen